Ultrahypofractionated radiotherapy yields non-inferior 10-year survival outcomes compared to conventional treatment in ...
Non-inferiority trials have become an essential instrument in clinical research, particularly when the goal is to demonstrate that an experimental treatment is not unacceptably worse than an ...
Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were ...
New study findings show that utilizing super-high-pressure non-compliant balloons (NCB) is non-inferior to intravascular lithotripsy (IVL) balloon catheters for lesion preparation and stent expansion ...
In July 2025, 3 4DMT announced its intent to accelerate its 4D-150 4FRONT phase 3 program in wet AMD and lay off approximately 25% of staff. 4DMT noted that this transition supported the company’s ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
The recent presentation of the long-term results of the JCOG0802 phase 3 trial has sparked discussion within the international thoracic surgical community. Initial 5-year results in 2022 reported a ...
EyePoint Pharmaceuticals receives a reiterated sell rating due to ongoing clinical and commercial uncertainties despite recent progress in DME and wet AMD trials. Duravyu (EYP-1901) showed positive ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results